First-line alectinib halts growth of alk+ nsclc more than crizotinib.
About 5% of cases of non-small-cell lung cancer are ALK-positive. Crizotinib has been the first medicine to target ALK specifically. It was approved by the FDA in 2011. Though the majority of patients benefit from crizotinib initially, the cancer typically progresses within a year. The newer anaplastic lymphoma kinase (ALK) inhibitor Alectinib has been shown […]
First-line alectinib halts growth of alk+ nsclc more than crizotinib. Read More »
